Lymphoma Treatment - Dr Gaurav Dixit

by Dr Gaurav Dixit DM Clinical Hematology, BMT Physician
Lymphoma is one of the most common types of blood cancer that begins in the cells of our lymph system. The disease can be examined by Dr Gaurav Dixit, a well-renowned Hematologistin Delhi.
Recommended Features
  • Chemotherapy
  • Radiation therapy
  • Bone marrow transplant
Learn more about Lymphoma Treatment - Dr Gaurav Dixit»

Review on Lymphoma Treatment - Dr Gaurav Dixit

Treatment option available
The lymphoma treatment depends on its type and stage, your overall health, and your preference. The goal of the treatment is to destroy as many as possible cancer cells to bring the disease into remission. Some of the lymphoma treatments are:

Chemotherapy: Some drugs are used to destroy fast-growing cancer cells. These drugs usually administered through veins or sometimes can be taken orally.

Radiation therapy: High powered beams of energy like X-ray and protons are used to kill cancer cells.

Bone marrow transplant: A high dose of chemotherapy and radiation is used to suppress the bone marrow, and then healthy bone marrow cells of the patient or donor are infused into the blood to build a healthy bone marrow.

Lymphoma treatment is planned individually, which has the best chance of success with the least damage to the long term health of the patient. If you are suffering from any type of lymphoma, then you have to visit the best lymphoma treatment in Delhi.

Related to Lymphoma Treatment - Dr Gaurav Dixit

Related Articles

Lymphoma Treatment Drugs Markets in China

March., 19, 2016, Mumbai, India: Market Reports on China presents the report, on “Lymphoma Treatment Drugs Markets in China”. This new study examines China's economic trends, investment environme...

Sponsor Ads

About Dr Gaurav Dixit Freshman   DM Clinical Hematology, BMT Physician

6 connections, 2 recommendations, 43 honor points.
Joined APSense since, October 15th, 2019, From New Delhi, Delhi, India.

Created on Nov 20th 2019 01:47. Viewed 436 times.


No comment, be the first to comment.
Please sign in before you comment.